Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have been given a consensus recommendation of “Moderate Buy” by the seventeen ratings firms that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, thirteen have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $104.4545.

GPCR has been the subject of several research reports. Guggenheim lifted their target price on Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday. Piper Sandler reaffirmed an “overweight” rating on shares of Structure Therapeutics in a report on Tuesday, October 28th. The Goldman Sachs Group raised shares of Structure Therapeutics to a “strong-buy” rating in a report on Tuesday. Morgan Stanley lifted their price target on shares of Structure Therapeutics from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Capricorn Fund Managers Ltd acquired a new stake in Structure Therapeutics in the fourth quarter worth $17,568,000. E. Ohman J or Asset Management AB acquired a new stake in shares of Structure Therapeutics in the 4th quarter worth about $314,000. Gilbert & Cook Inc. acquired a new stake in shares of Structure Therapeutics in the 4th quarter worth about $395,000. JPMorgan Chase & Co. lifted its position in Structure Therapeutics by 37.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 58,148 shares of the company’s stock valued at $1,628,000 after purchasing an additional 15,706 shares during the last quarter. Finally, Alyeska Investment Group L.P. acquired a new position in Structure Therapeutics during the 3rd quarter valued at about $6,856,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Trading Down 1.6%

Structure Therapeutics stock opened at $90.37 on Monday. Structure Therapeutics has a 52 week low of $13.22 and a 52 week high of $94.90. The stock has a market cap of $5.48 billion, a P/E ratio of -74.07 and a beta of -2.05. The stock has a 50 day moving average of $60.89 and a 200-day moving average of $36.51.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.01). As a group, equities analysts predict that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.